Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Reports from University of Texas add new data to research in breast cancer
November 20th, 2008
According to recent research from the United States, " The majority of estrogen receptor ( ER)-positive cancers are sensitive to endocrine therapy and may not derive much further benefit from chemotherapy, but a subset are potentially chemotherapy sensitive. Molecular diagnostic tests allow the identification of these various subsets with some accuracy." "The goal of the current analysis was to examine how the proportion of cases in the various risk ( recurrence score [RS]) categories of a commercially available multigene assay influences the power of randomized trials to show benefit from adjuvant chemotherapy. We modeled 10-year disease-free survival (DFS) for...
Source: Women's Health Weekly (2008-11-20)
|
